Immodulon links up with myTomorrows over access program

Privately-held UK biotech Immodulon has teamed up with Dutch firm myTomorrows to develop an Expanded Access Program (EAP) for the unlicensed drug IMM-101.

The immuno-oncology specialist is progressing IMM-101 in a clinical development program as a potential treatment in several cancer settings. The EAP will support the supply in Europe of IMM-101 when prescribed on a named patient basis for those who have no other treatment options.

Steve Glass, chief operating officer of myTomorrows, said: “I am delighted that myTomorrows is to strengthen the relationship with Immodulon. With our unique online platform, combined with our global capabilities of supporting expanded access and real-world data collection, we aim to accelerate access to a medicine in development.”